Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy.

ABSTRACT: Immune-checkpoint blockade (ICB) has shown remarkable clinical success in boosting antitumor immunity. However, the breadth of its cellular targets and specific mode of action remain elusive. We find that tumor-infiltrating follicular regulatory T (T_FR) cells are prevalent in tumor tissues of several cancer types. They are primarily located within tertiary lymphoid structures and exhibit superior suppressive capacity and in vivo persistence as compared with regulatory T cells, with which they share a clonal and developmental relationship. In syngeneic tumor models, anti-PD-1 treatment increases the number of tumor-infiltrating T_FR cells. Both T_FR cell deficiency and the depletion of T_FR cells with anti-CTLA-4 before anti-PD-1 treatment improve tu

SUBMITTER: Eschweiler S 

PROVIDER: S-EPMC8434898 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature